Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients
Browse Categories
ABSTRACT
Objective: This study aimed to investigate the potential parameters associated with imaging progression on chest CT from coronavirus disease 19 (COVID-19) patients. Results: The average age of 273 COVID-19 patients enrolled with imaging progression were older than those without imaging progression (p = 0.006). The white blood cells, platelets, neutrophils and acid glycoprotein were all decreased in imaging progression patients (all p < 0.05), and monocytes were increased (p = 0.025). The parameters including homocysteine, urea, creatinine and serum cystatin C were significantly higher in imaging progression patients (all p < 0.05), while eGFR decreased (p < 0.001). Monocyte-lymphocyte ratio (MLR) was significantly higher in imaging progression patients compared to that in imaging progression-free ones (p < 0.001). Logistic models revealed that age, MLR, homocysteine and period from onset to admission were factors for predicting imaging progression on chest CT at first week from COVID-19 patients (all p < 0.05). Conclusion: Age, MLR, homocysteine and period from onset to admission could predict imaging progression on chest CT from COVID-19 patients. Methods: The primary outcome was imaging progression on chest CT. Baseline parameters were collected at the first day of admission. Imaging manifestations on chest CT were followed-up at (6±1) days.
INTRODUCTION
Since the end of 2019, a novel coronavirus with person-to-person transmission has spread to many other countries worldwide [1–5]. Previous epidemiology report uncovered that the epidemic of coronavirus disease 2019 (COVID-19) has doubled every 7.4 day in its early stage, with an average serial interval of 7.5 days [3]. Early information estimated that the basic reproductive number R0 was estimated to be 1.4 – 2.5 reported by WHO [2]. The pandemic is accelerating at an exponential rate and at risk of escalating into a global health emergency [2]. The mortality of coronavirus disease 2019 (COVID-19) patients in China is approximately 2.3%, compared with 9.6% of severe acute respiratory syndrome (SARS) and 34.4% of middle east respiratory syndrome (MERS) reported by WHO [6]. Even this virus is not as fetal as people thought, the transmissibility is far exceeding that of SARS and MERS [7]. Although many clinical and epidemiological literatures have been published [3–6, 8–10], the spread in still ongoing and the early warning parameters for disease progression remain incomplete.
Compared to symptoms, chest CT findings were more rapid and frequent [11, 12]. The imaging performance on chest CT scans from COVID-19 patients mainly manifested as bilateral ground-glass opacities (GGOs) in the lung periphery [13]. In a retrospective cohort, chest CTs of 121 symptomatic COVID-19 patients have been reviewed. Bilateral lung involvement was observed in 10/36 early patients (28%), 25/33 intermediate patients (76%), and 22/25 late patients (88%) [11]. Currently, chest CT is used to assess the severity of lung involvement in COVID-19 pneumonia [14]. In a cohort study, 85.7% (54/63) confirmed COVID-19 patients developed imaging progression including enlarged and increased extent of GGOs and consolidation at early follow-up chest CT scans [12]. That is, short-term imaging progression on chest CT from COVID-19 patients should be early predicted and intervened.
RESULTS
Imaging performance of progression and progression-free patients
As shown in Figure 1, most mild type COVID-19 patients had bilateral and peripheral GGOs, consolidation and linear opacities imaging involvements on chest CT at the first admission day. Some patients had no remarkable hallmarks. At the first six (±1) day, enlarged and increased GGOs, consolidation, solid nodules and fibrous stripes were observed for patients suffered from imaging progression on chest CT scans. On the contrary, the GGOs, consolidation and linear opacities were partly resolved and decreased for imaging progression-free patients.
Baseline characteristics and inflammatory model comparisons between imaging progression and progression-free patients
In total, 71 COVID-19 patients suffered from imaging progression on chest CT at first week after admission, and the other 202 patients were imaging progressionfree on chest CT. As summarized in Table 1, the patients in imaging progression group were significantly older than those in imaging progressionfree group (p = 0.006, Table 1). More patients were treated with gamma globulin and thymosin in imaging progression group compared to those without imaging progression (p = 0.022 and p = 0.001, respectively, Table 1). In blood routine tests, the white blood cells (WBC), platelets and neutrophils were significantly lower in imaging progression patients than those in imaging progression-free ones (p = 0.025, p = 0.044 and p = 0.014, respectively, Table 1), while the monocytes were significantly higher in imaging progression patients (p = 0.025, Table 1). Additionally, acid glycoprotein was significantly lower in imaging progression patients (p = 0.037, Table 1). In liver function tests, gamma-glutamyl transferase (GGT) levels were significantly higher in imaging progression-free patients (p = 0.045, Table 1), while homocysteine levels were significantly higher in imaging progression patients (p = 0.006, Table1). In kidney function tests, urea, creatinine and serum cystatin C levels were significantly higher in imaging progression patients compared to those in imaging progression-free ones (p = 0.011, p = 0.007, respectively, Table 1). As we expected, the estimated glomerular filtration rate (eGFR) levels were significantly decreased in imaging progression patients (p < 0.001, Table 1). No differences were found in cardiac markers and coagulation function tests.
Co-manifestations on chest CT and outcomes
As summarized in Table 2, except for common manifestations on chest CT, chronic inflammatory
manifestation, chronic bronchitis / emphysema, pericardial effusion, pleural effusion, bullae of lung and obsolete tuberculosis were the most frequent imaging co-manifestations in COVID-19 patients. COVID-19 patients with imaging progression had significantly higher frequency of chronic inflammatory manifestation than those without imaging progression (12.7% vs. 3.5%, p = 0.005, Table 2). No differences were found in distributions of chronic bronchitis / emphysema, pericardial effusion, pleural effusion, bullae of lung and obsolete tuberculosis between these two groups (Table 2).
Parameters associated with imaging progression on chest CT
Variables including age, gender, disease history, epidemiology, chest CT imaging, therapeutic strategies, period from onset to admission, ALRI, APRI, MLR, NLR, PLR, SII, WBC, neutrophils, lymphocytes, monocytes, platelet, red blood cells (RBC), hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), GGT, lactate dehydrogenase (LDH), total bilirubin (TBiL), albumin, globulin, urea, creatinine, eGFR, lactic acid, haptoglobin, acid glycoprotein, cystatin C, homocysteine, retinolbinding protein, cardiac troponin (cTnI), myoglobin, brain natriuretic peptide prohormone (pro-BNP), prothrombin time, prothrombin activity (PTA), international normalized ratio (INR), D-dimer were included in the univariate analysis. As presented in Table 3, age, gamma globulin therapy, thymosin therapy, MLR, serum cystatin C, homocysteine, eGFR and period from onset to admission were potential parameters associated with imaging progression (all p < 0.05, Table 3). When these parameters were included in the multivariate model, age, MLR and homocysteine were significantly correlated with imaging progression on chest CT from COVID-19 patients (RR = 2.28, 95%CI = 1.12 – 4.34, p = 0.012; RR = 7.69, 95%CI = 1.67 – 35.55, p = 0.009 and RR = 3.17, 95%CI = 1.01 – 9.96, p = 0.048; respectively, Table 3). In addition, COVID-19 patients with period from onset to admission ≥ 4 days might have lower risk to develop imaging progression on chest CT at first week after admission (RR = 0.35, 95%CI = 0.19 – 0.67, p = 0.001, Table 3).
Moreover, no acute bacterial or other viral co-infection performances on chest CT were found in these COVID19 patients.
All these COVID-19 patients did not develop severe conditions, no one died during our follow up.
Parameters associated with imaging progression on chest CT
Variables including age, gender, disease history, epidemiology, chest CT imaging, therapeutic strategies, period from onset to admission, ALRI, APRI, MLR, NLR, PLR, SII, WBC, neutrophils, lymphocytes, monocytes, platelet, red blood cells (RBC), hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), procalcitonin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), GGT, lactate dehydrogenase (LDH), total bilirubin (TBiL), albumin, globulin, urea, creatinine, eGFR, lactic acid, haptoglobin, acid glycoprotein, cystatin C, homocysteine, retinolbinding protein, cardiac troponin (cTnI), myoglobin, brain natriuretic peptide prohormone (pro-BNP), prothrombin time, prothrombin activity (PTA), international normalized ratio (INR), D-dimer were included in the univariate analysis. As presented in Table 3, age, gamma globulin therapy, thymosin therapy, MLR, serum cystatin C, homocysteine, eGFR and period from onset to admission were potential parameters associated with imaging progression (all p < 0.05, Table 3). When these parameters were included in the multivariate model, age, MLR and homocysteine were significantly correlated with imaging progression on chest CT from COVID-19 patients (RR = 2.28, 95%CI = 1.12 – 4.34, p = 0.012; RR = 7.69, 95%CI = 1.67 – 35.55, p = 0.009 and RR = 3.17, 95%CI = 1.01 – 9.96, p = 0.048; respectively, Table 3). In addition, COVID-19 patients with period from onset to admission ≥ 4 days might have lower risk to develop imaging progression on chest CT at first week after admission (RR = 0.35, 95%CI = 0.19 – 0.67, p = 0.001, Table 3).
Table 1. Baseline characteristics of COVID-19 patients.
Variables |
Chest CT Progression group (n = 71)
| Chest CT Progression-free group (n = 202) |
p-value |
Age, years, mean ± SD | 53.5 ± 1.9 | 47.6 ± 1.1 | 0.006 |
Male, n (%) | 33 (46.5) | 101 (50) | 0.61 |
Disease history, n (%) | |||
None | 48 (67.6) | 143 (70.8) | |
Hypertension | 13 (18.3) | 27 (13.4) | |
Diabetes | 7 (9.9) | 11 (5.4) | |
Fatty liver disease | 12 (16.9) | 27 (13.4) | |
Others | 3 (4.2) | 21 (10.4) | |
Epidemiology, n (%) | |||
Hubei sojourning history | 43 (56.3) | 108 (53.5) | 0.301 |
Contact with COVID-19 patients | 27 (38.0) | 72 (35.6) | 0.719 |
Therapeutic strategy, n (%) | |||
Antivirus drugs | 58 (81.7) | 141 (69.8) | 0.053 |
Antibiotics | 22 (31.0) | 46 (22.8) | 0.169 |
Gamma globulin | 13 (18.3) | 17 (8.4) | 0.022 |
Thymosin | 20 (28.2) | 23 (11.4) | 0.001 |
Glucocorticoid | 10 (14.1) | 17 (8.4) | 0.169 |
TCM decoction | 5 (7.0) | 25 (12.4) | 0.216 |
TCM patent | 27 (38.0) | 58 (28.7) | 0.145 |
Chest CT imaging, n (%) | |||
Bilateral lung lesion | 60 (84.5) | 177 (87.6) | |
Single lung lesion | 11 (15.5) | 25 (12.4) | |
Blood routine tests, mean ± SD | |||
WBC, 103/mm3 | 4.6 ± 0.1 | 5.2 ± 0.1 | 0.025 |
RBC, 104/mm3 | 4.4 ± 0.1 | 4.5 ± 0.04 | 0.334 |
Hemoglobin, g/L | 135.1 ± 1.7 | 136.7 ± 1.1 | 0.465 |
Platelet, 103/mm3 | 176.0 ± 6.6 | 195.0 ± 5.1 | 0.044 |
Neutrophils, 103/mm3 | 2.9 ± 0.1 | 3.5 ± 0.1 | 0.014 |
Lymphocytes, 103/mm3 | 1.2 ± 0.1 | 1.3 ± 0.04 | 0.342 |
Monocytes, 103/mm3 | 0.5 ± 0.03 | 0.4 ± 0.01 | 0.025 |
Hypersensitive CRP, mg/L, mean ± SD | 17.5 ± 2.4 | 18.7 ± 1.6 | 0.697 |
ESR, mm/Hour, mean ± SD | 56.9 ± 4.3 | 64.5 ± 2.7 | 0.148 |
Procalcitonin, ng/ml, mean±SD | 0.05 ± 0.01 | 0.09 ± 0.05 | 0.687 |
Acid glycoprotein, mg/dl, mean ± SD | 140.9 ± 5.6 | 154.5 ± 3.3 | 0.037 |
Liver function tests, mean ± SD | |||
ALT, U/L | 27.6 ± 2.3 | 27.6 ± 1.4 | 0.995 |
AST, U/L | 29.4 ± 1.7 | 29.2 ± 1.6 | 0.958 |
GGT, U/L | 29.5 ± 2.5 | 38.6 ± 2.5 | 0.045 |
LDH, U/L | 244.4 ± 10.4 | 248.8 ± 5.8 | 0.703 |
TBiL, μmol/L | 8.4 ± 0.4 | 9.2 ± 0.3 | 0.116 |
Albumin, g/L | 40.8 ± 0.4 | 41.1 ± 0.3 | 0.537 |
Globulin, g/L | 28.8 ± 0.5 | 29.0 ± 0.3 | 0.693 |
Homocysteine, μmol/L | 10.7 ± 0.5 | 9.3 ± 0.2 | 0.006 |
Renal function test, mean ± SD | |||
Urea, mmol/L | 5.1 ± 0.2 | 4.5 ± 0.1 | 0.011 |
Creatinine, μmol/L | 70.7 ± 3.0 | 63.0 ± 1.3 | 0.007 |
Serum cystatin C, mg/L | 1.0 ± 0.04 | 0.8 ± 0.01 | < 0.001 |
eGFR, ml/(min×1.73m2) | 101.3 ± 3.1 | 116.3 ± 1.9 | < 0.001 |
Lactic acid, mmol/L, mean ± SD | 2.8 ± 0.1 | 2.8 ± 0.04 | 0.936 |
Haptoglobin, mg/dl, mean ± SD | 209.2 ± 12.0 | 229.6 ± 7.0 | 0.142 |
Retinol-binding protein, mg/L, mean ± SD 27.8 ± 1.4 26.4 ± 0.7 0.327 Cardiac markers, mean ± SD | 27.8 ± 1.4 | 26.4 ± 0.7 | 0.327 |
cTnI, ng/ml | 0.029 ± 0.004 | 0.033 ± 0.003 | 0.455 |
Myoglobin, ng/ml | 17.5 ± 3.0 | 14.7 ± 2.9 | 0.59 |
Pro-BNP, pg/ml | 73.5 ± 13.7 | 67.6 ± 7.2 | 0.692 |
Coagulation function tests, mean ± SD | |||
INR | 1.01 ± 0.008 | 1.02 ± 0.008 | 0.424 |
PTA | 99.9 ± 1.2 | 99.0 ± 0.8 | 0.579 |
Prothrombin time, second | 13.4 ± 0.08 | 13.5 ± 0.08 | 0.402 |
D-Dimer, μg/ml | 0.55 ± 0.06 | 0.77 ± 0.11 | 0.254 |
Table 3. parameters associated with imaging progression in chest CT from COVID-19 patients#.
Variables |
Univariate RR |
Univariate 95%CI |
p value |
Multivariate RR |
Multivariate 95%CI |
p value |
Age, years | ||||||
<60 | reference | - | 1.0 | reference | - | 1.0 |
≥60 | 2.72 | 1.55-4.78 | < 0.001 | 2.28 | 1.12-4.34 | 0.012 |
Gamma globulin, yes vs. no | 2.44 | 1.12-5.32 | 0.025 | 1.08 | 0.38-3.08 | 0.89 |
Thymosin, yes vs. no | 3.05 | 1.55-6.0 | 0.001 | 2.32 | 0.94-5.73 | 0.069 |
MLR, per increase 1 unit | 12.2 | 3.09-48.23 | < 0.001 | 7.69 | 1.67-35.55 | 0.009 |
Serum cystatin C, mg/L | ||||||
< 1.03 | reference | - | 1.0 | reference | - | 1.0 |
> 1.03 | 2.8 | 1.35-5.82 | 0.006 | 0.79 | 0.28-2.2 | 0.65 |
Homocysteine, μmol/L | ||||||
< 15.4 | reference | - | 1.0 | reference | - | 1.0 |
> 15.4 | 3.54 | 1.23-10.14 | 0.019 | 3.17 | 1.01-9.96 | 0.048 |
eGFR, ml/(min×1.73m2) | ||||||
> 90 | reference | - | 1.0 | reference | - | 1.0 |
< 90 | 2.97 | 1.54-5.75 | 0.001 | 1.63 | 0.67-4.0 | 0.281 |
Period from onset to admission, days | ||||||
< 4 | reference | - | 1.0 | reference | - | 1.0 |
≥ 4 | 0.36 | 0.20-0.64 | 0.001 | 0.35 | 0.19-0.67 | 0.001 |
TCM, Traditional Chinese Medicine; WBC, white blood cells; RBC, red blood cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; TBiL, total bilirubin; eGFR, estimated glomerular filtration rate; cTnI, cardiac troponin; Pro-BNP, Brain natriuretic peptide prohormone; INR, international normalized ratio; PTA, prothrombin activity.
Predictive values of MLR and age for imaging progression on chest CT
Table 2. Co-manifestations on chest CT in COVID-19 patients.
Co-manifestations, n (%) |
Chest CT Progression Group (n = 71) |
Chest CT Progression-Free Group (n = 202) | p-value |
Chronic inflammatory manifestations | 9 (12.7) | 7 (3.5) | 0.005 |
Chronic bronchitis / emphysema | 2 (2.8) | 2 (1.0) | 0.271 |
Pericardial effusion | 1 (1.4) | 1 (0.5) | 0.438 |
Pleural effusion | 1 (1.4) | 0 (0) | 0.091 |
Bullae of lung | 1 (1.4) | 2 (1.0) | 0.771 |
Obsolete tuberculosis | 2 (2.8) | 1 (0.5) | 0.107 |
Table 3. parameters associated with imaging progression in chest CT from COVID-19 patients#.
Variables |
Univariate RR |
Univariate 95%CI |
p value |
Multivariate RR |
Multivariate 95%CI |
p value |
Age, years | ||||||
<60 | reference | - | 1.0 | reference | - | 1.0 |
≥60 | 2.72 | 1.55-4.78 | < 0.001 | 2.28 | 1.12-4.34 | 0.012 |
Gamma globulin, yes vs. no | 2.44 | 1.12-5.32 | 0.025 | 1.08 | 0.38-3.08 | 0.89 |
Thymosin, yes vs. no | 3.05 | 1.55-6.0 | 0.001 | 2.32 | 0.94-5.73 | 0.069 |
MLR, per increase 1 unit | 12.2 | 3.09-48.23 | < 0.001 | 7.69 | 1.67-35.55 | 0.009 |
Serum cystatin C, mg/L | ||||||
< 1.03 | reference | - | 1.0 | reference | - | 1.0 |
> 1.03 | 2.8 | 1.35-5.82 | 0.006 | 0.79 | 0.28-2.2 | 0.65 |
Homocysteine, μmol/L | ||||||
< 15.4 | reference | - | 1.0 | reference | - | 1.0 |
> 15.4 | 3.54 | 1.23-10.14 | 0.019 | 3.17 | 1.01-9.96 | 0.048 |
eGFR, ml/(min×1.73m2) | ||||||
> 90 | reference | - | 1.0 | reference | - | 1.0 |
< 90 | 2.97 | 1.54-5.75 | 0.001 | 1.63 | 0.67-4.0 | 0.281 |
Period from onset to admission, days | ||||||
< 4 | reference | - | 1.0 | reference | - | 1.0 |
≥ 4 | 0.36 | 0.20-0.64 | 0.001 | 0.35 | 0.19-0.67 | 0.001 |
DISCUSSION
Table 4. Predictive values of MLR model, age, and homocysteine for imaging progression on chest CT from COVID-19 patients.
| Estimate | 95%CI |
MLR |
|
|
Cutoff | 0.51 | - |
Sensitivity | 0.44 | 0.32 – 0.56 |
Specificity | 0.79 | 0.72 – 0.84 |
Positive predictive value | 0.42 | 0.34 – 0.54 |
Negative predictive value | 0.80 | 0.71 – 0.85 |
Age, years |
|
|
Cutoff | 51 | - |
Sensitivity | 0.65 | 0.53 – 0.76 |
Specificity | 0.58 | 0.51 – 0.65 |
Positive predictive value | 0.35 | 0.29 – 0.48 |
Negative predictive value | 0.83 | 0.74 – 0.86 |
Homocysteine, μmol/L |
|
|
Cut off | 10.58 |
|
Sensitivity | 0.42 | 0.31 – 0.55 |
Specificity | 0.79 | 0.72 – 0.84 |
Positive predictive value | 0.41 | 0.33 – 0.53 |
Negative predictive value | 0.80 | 0.70 – 0.85 |
MATERIALS AND METHODS
CONFLICTS OF INTEREST
FUNDING
REFERENCES
- Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395:514–23. https://doi.org/10.1016/S0140-6736(20)30154-9 PMID:31986261
- Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020; 48:155–163. https://doi.org/10.1007/s15010-020-01401-y PMID:32072569
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X, Xiang N, Wu Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382:1199–207. https://doi.org/10.1056/NEJMoa2001316 PMID:31995857
- Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM, Pham QD. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020; 382:872–74. https://doi.org/10.1056/NEJMc2001272 PMID:31991079
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, et al, and China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382:727–33. https://doi.org/10.1056/NEJMoa2001017 PMID:31978945
- She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020; 9:19. https://doi.org/10.1186/s40169-020-00271-z PMID:32078069
- Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020; 27:taaa021. https://doi.org/10.1093/jtm/taaa021 PMID:32052846
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–13. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID:32007143
- Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41:145–151. https://doi.org/10.3760/cma.j.issn.0254-2020.02.003
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. [Epub ahead of print]. https://doi.org/10.1001/jama.2020.1585 PMID:32031570
- Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li S, Shan H, Jacobi A, Chung M. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. 2020; [Epub ahead of print]. https://doi.org/10.1148/radiol.2020200463 PMID:32077789
- Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020. [Epub ahead of print]. https://doi.org/10.1007/s00330-020-06731-x PMID:32055945
- Kim H. Outbreak of novel coronavirus (COVID-19): what is the role of radiologists? Eur Radiol. 2020. [Epub ahead of print]. https://doi.org/10.1007/s00330-020-06748-2 PMID:32072255
- Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020. [Epub ahead of print]. https://doi.org/10.1148/radiol.2020200370 PMID:32053470
- Kanne JP, Chest CT. Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist. Radiology. 2020; 295:16–17. https://doi.org/10.1148/radiol.2020200241 PMID:32017662
- Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, Jacobi A, Li K, Li S, Shan H. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020; 295:202–07. https://doi.org/10.1148/radiol.2020200230 PMID:32017661
- Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020. [Epub ahead of print]. https://doi.org/10.1001/jama.2020.2131 PMID:32058570
- Wang XF, Yuan J, Zheng YJ, Chen J, Bao YM, Wang YR, Wang LF, Li H, Zeng JX, Zhang YH, Liu YX, Liu L. [Retracted: clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]. Zhonghua Er Ke Za Zhi. 2020; 58:E008. https://doi.org/10.3760/cma.j.issn.0578-2020.0008
- Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020. [Epub ahead of print]. https://doi.org/10.1542/peds.2020-0702 PMID:32179660
- Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020; 92:441–47. https://doi.org/10.1002/jmv.25689 PMID:31994742
- Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020. [Epub ahead of print]. https://doi.org/10.1097/CM9.0000000000000744 PMID:32044814
- Zhou L, Liu HG. [Early detection and disease assessment of patients with novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43:E003. https://doi.org/10.3760/cma.j.issn.1001-2020.0003
- Desforges M, Miletti TC, Gagnon M, Talbot PJ. Activation of human monocytes after infection by human coronavirus 229E. Virus Res. 2007; 130:228–40. https://doi.org/10.1016/j.virusres.2007.06.016 PMID:17669539
- Yilla M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS, Bellini WJ, Anderson LJ.
- Collins AR. In vitro detection of apoptosis in monocytes/macrophages infected with human coronavirus. Clin Diagn Lab Immunol. 2002; 9:1392–95. https://doi.org/10.1128/cdli.9.6.1392-1395.2002 PMID:12414783
- Kohyama S, Ohno S, Suda T, Taneichi M, Yokoyama S, Mori M, Kobayashi A, Hayashi H, Uchida T, Matsui M. Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. Antiviral Res. 2009; 84:168–77. https://doi.org/10.1016/j.antiviral.2009.09.004 PMID:19748524
- Ohno S, Kohyama S, Taneichi M, Moriya O, Hayashi H, Oda H, Mori M, Kobayashi A, Akatsuka T, Uchida T, Matsui M. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A*0201 transgenic mice. Vaccine. 2009; 27:3912–20. https://doi.org/10.1016/j.vaccine.2009.04.001 PMID:19490987
- He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005; 9:323–30. https://doi.org/10.1016/j.ijid.2004.07.014 PMID:16095942
- Chu H, Zhou J, Wong BH, Li C, Chan JF, Cheng ZS, Yang D, Wang D, Lee AC, Li C, Yeung ML, Cai JP, Chan IH, et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. J Infect Dis. 2016; 213:904–14. https://doi.org/10.1093/infdis/jiv380 PMID:26203058
- National Health Commission of the People’s Republic of China. Diagnosis and management program of novel coronavirus-infected pneumonia (4th edition). 2020. http://www.gov.cn/zhengce/zhengceku/2020-2001/2028/5472673/files/5472670f5472696c5472610 cc5472609d5472674d5472636a5472676f5472679a54 pdf
- National Health Commission of the People’s Republic of China. Diagnosis and management program of novel coronavirus pneumonia (6th edition). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/208334 a208326dd202094d202329df202351d202007da20200 8aefc202002/files/b202218cfeb202001bc254639af202
- 227f202922bf202006b202817.pdf
- Guo YH, Chen FY, Wang GS, Chen L, Gao W. Diet-induced hyperhomocysteinemia exacerbates vascular reverse remodeling of balloon-injured arteries in rat. Chin Med J (Engl). 2008; 121:2265–71. https://doi.org/10.1097/00029330-200811020-00011 PMID:19080331
- Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001; 107:675–83. https://doi.org/10.1172/JCI10588 PMID:11254667
- Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006 (6 Suppl); 136:1741S–49S. https://doi.org/10.1093/jn/136.6.1741S PMID:16702349
- Deminice R, da Silva RP, Lamarre SG, Brown C, Furey GN, McCarter SA, Jordao AA, Kelly KB, King-Jones K, Jacobs RL, Brosnan ME, Brosnan JT. Creatine supplementation prevents the accumulation of fat in the livers of rats fed a high-fat diet. J Nutr. 2011; 141:1799–804. https://doi.org/10.3945/jn.111.144857 PMID:21880953
- Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506–12. https://doi.org/10.1210/jc.2006-2190 PMID:17456578
- Wijekoon EP, Brosnan ME, Brosnan JT. Homocysteine metabolism in diabetes. Biochem Soc Trans. 2007; 35:1175–79. https://doi.org/10.1042/BST0351175 PMID:17956306
- Abike F, Engin AB, Dunder I, Tapisiz OL, Aslan C, Kutluay L. Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias. Arch Gynecol Obstet. 2011; 284:209–14. https://doi.org/10.1007/s00404-010-1650-7 PMID:20740364
- Deminice R, Silva TC, de Oliveira VH. Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: A meta-analysis. World J Virol. 2015; 4:147–55. https://doi.org/10.5501/wjv.v4.i2.147 PMID:25964880
- Roblin X, Pofelski J, Zarski JP. [Steatosis, chronic hepatitis virus C infection and homocysteine]. Gastroenterol Clin Biol. 2007; 31:415–20. https://doi.org/10.1016/S0399-8320(07)89402-4 PMID:17483780
- Lopez-Raton M, Rodriguez-Alvarez MX, Suarez CC, Sampedro FG. OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests. J Stat Softw. 2014; 61:1–36. https://doi.org/10.18637/jss.v061.i08